Assessment of nevirapine bioavailability from targeted sites in the human gastrointestinal tract

Journal of Clinical Pharmacology

Volumn 49, Issue 12, 2009, Pages 1417-1425

  MacHa, Sreeraj ^a   Yong, Chan Loi ^a   MacGregor, Thomas R ^a   Castles, Mark ^a   Quinson, Anne Marie ^a   Rouyrre, Nicolas ^b   Wilding, Ian ^c  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^b BOEHRINGER INGELHEIM   (France)

^c PHARMACEUTICAL PROFILES LTD   (United Kingdom)

Author keywords

Enterion capsule; Gamma scintigraphy; GI site absorption; Nevirapine

Indexed keywords

AMINOTRANSFERASE; NEVIRAPINE;

AREA UNDER THE CURVE; ARTICLE; ASCENDING COLON; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DESCENDING COLON; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; GAMMA SCINTIGRAPHY; GASTROINTESTINAL TRACT; HEADACHE; HUMAN; HUMAN EXPERIMENT; ILEUM; JEJUNUM; LABORATORY TEST; LETHARGY; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; SOMNOLENCE; STOMACH EMPTYING; SUSPENSION; TENSION HEADACHE;

BIOLOGICAL AVAILABILITY; CAPSULES; DRUG DELIVERY SYSTEMS; HUMANS; INTESTINAL ABSORPTION; MALE; NEVIRAPINE; ORGAN SPECIFICITY; RADIONUCLIDE IMAGING; TELEMETRY;

EID: 71449125747     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009344856     Document Type: Article

References (31)

1. Bacolla A., Shih C. -K, Rose JM, et al. Amino acid substitutions in HIV-1 reverse transcriptase with corresponding residues from HIV-2: effect on kinetic constants and inhibition by non-nucleoside analogs. J Biol Chem. 1993 ; 268: 16571-16577.
2. Cheeseman SH, Havlir D., McLaughlin MM, et al. Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus. J Acquir Immune Defic Syndr Hum Retrovirol. 1995 ; 8: 141-151.
3. Raffi F., Reliquet V., Ferre V., et al. The VIRGO study: nevirapine, didanosine and stavudine combination therapy in antiretroviral-naive HIV-1-infected adults. Antivir Ther. 2000 ; 5: 267-272.
4. Montaner JS, Reiss P., Cooper D., et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA. 1998 ; 279: 930-937.
5. Skowron D., Leoung G., Hall DB, et al. Pharmacokinetic evaluation and short-term activity of stavudine, nevirapine, and nelfinavir therapy in HIV-1-infected adults. J Acquir Immune Defic Syndr. 2004 ; 35: 351-358.
6. Haubrich RH, Little SJ, Currier JS, et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. AIDS. 1999 ; 13: 1099-1107.
7. Hawkins T. Impact of once- and twice-daily dosing regimens on adherence and overall safety. AIDS Read. 2004 ; 14: 320-325.
8. Lamson MJ, Sabo JP, MacGregor TR, et al. Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteers. Biopharm Drug Dispos. 1999 ; 20: 285-291.
9. Kappelhoff BS, Huitema AD, van Leth F., et al. Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN study. HIV Clin Trials. 2005 ; 6: 254-261.
10. Ribera E., Rodriguez-Pardo D., Rubio M., et al. Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients. Antivir Ther. 2005 ; 10: 605-614. (Pubitemid 41224952)
11. Anekthananon T., Ratanasuwan W., Techasathit W., Sonjai A., Suwanagool S. Safety and efficacy of a simplified fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) for the treatment of advanced HIV-infected patients: a 24-week study. J Med Assoc Thai. 2004 ; 87: 760-767.
12. van Heeswijk RP, Veldkamp AI, Mulder JW, et al. The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. AIDS. 2000 ; 14: F77 - F82.
13. Wilding IR, Coupe AJ, Davis SS The role of γ-scintigraphy in oral drug delivery. Adv Drug Del Rev. 2001 ; 46: 103-124.
14. Connor AL, Wray H., Cottrell J., Wilding IR A scintigraphic study to investigate the potential for altered gut distribution of loperamide from loperamide-simethicone formulation in man. Eur J Pharm Sci. 2001 ; 13: 369-374.
15. Wilding IR Bioequivalence testing for locally acting gastrointestinal products using gamma scintigraphy. J Clin Pharm. 2002 ; 42: 1200-1210.
16. Dobson CL, Davis SS, Chauhan S., Sparrow RA, Wilding IR The effect of ileal brake activators on the oral bioavailability of atenolol in man. Int J Pharm. 2002 ; 248: 61-70.
17. Cole ET, Scott RA, Connor AL, et al. Enteric coated HPMC capsules designed to achieve intestinal targeting. Int J Pharm. 2002 ; 231: 83-95.
18. Kwei GY, Novak LB, Hettrick LA, et al. Regiospecific intestinal absorption of the HIV protease inhibitor L-735,524 in beagle dogs. Pharm Res. 1995 ; 12: 884-888.
19. Wilding IR Site-specific drug delivery in the gastrointestinal tract. Crit Rev Ther Drug Carrier Syst. 2000 ; 17: 557-620.
20. Staib AH, Loew D., Harder S., Graul EH, Pfab R. Measurement of theophylline absorption from different regions of the gastrointestinal tract using a remote controlled drug delivery device. Eur J Clin Pharmacol. 1986 ; 30: 691-697.
21. Harder S., Fuhr U., Beermann D., Staib AH Ciprofloxacin absorption in different regions of the human gastrointestinal tract: investigations with the HF capsule. Br J Clin Pharmacol. 1990 ; 30: 35-39.
22. Wilding IR, Hirst PH, Connor AL Development of new engineering-based capsule for human drug absorption studies. Pharm Sci Tech Today. 2000 ; 3: 385-392.
23. TM capsule. Modified Release Drug Deliv Technol. 2002 ; 24: 273-298.
24. Chaudhuri TK Use of 99mTc-DTPA for measuring gastric emptying time. J Nucl Med. 1973 ; 15: 391-395.
25. Rowland LS, MacGregor TR, Campbell SJ, Jenkins R., Pearsall AB, Morris JP Quantitation of five nevirapine oxidative metabolites in human plasma using liquid chromatography-tandem mass spectrometry. J Chromatogr B. 2007 ; 856: 252-260.
26. Wagner JG, Nelson E. Kinetic analysis of blood levels and urinary excretion in the absorptive phase after single doses of drug. J Pharm Sci. 1964 ; 53: 1392.
27. Coupe AJ, Davis SS, Wilding IR Variation in gastrointestinal transit of pharmaceutical dosage forms in healthy subjects. Pharm Res. 1991 ; 8: 360-364.
28. Davis SS Evaluation of the gastrointestinal transit of pharmaceutical dosage forms using the technique of gamma scintigraphy. S.T.P. Pharma Pratiques. 1986 ; 2: 1015-1022.
29. Hardy JG, Wilson CG, Wood E. Drug delivery to the proximal colon. J Pharm Pharmacol. 1985 ; 37: 874-877.
30. OReilly S., Wilson CG, Hardy JG Influence of food on the gastric emptying of multiparticulate dosage forms. Int J Pharm. 1987 ; 34: 213-216.
31. Hawi A., Bell G. Preformulation studies of nevirapine, a reverse transcriptase inhibitor. Pharm Res. 1994 ; 11 (suppl): S236.